MarketCap
Facebook
X
Telegram
Cardiovascular Systems Total Assets | CSII
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 323 M | 353 M | 340 M | 219 M | 203 M | 194 M | 142 M | 171 M | 182 M | 96.9 M | 63.1 M | 46.8 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 353 M | 46.8 M | 194 M |
Quarterly Total Assets Cardiovascular Systems
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 312 M | 312 M | 312 M | 324 M | 326 M | 332 M | 326 M | 332 M | 347 M | 353 M | 349 M | 342 M | 224 M | 217 M | 224 M | 211 M | 207 M | 200 M | 207 M | 195 M | 190 M | 190 M | 190 M | 187 M | 159 M | 138 M | 159 M | 145 M | 151 M | 162 M | 151 M | 179 M | 181 M | 182 M | 181 M | 185 M | 181 M | 95.1 M | 181 M | 99 M | 56.6 M | 60.1 M | 56.6 M | 49.8 M | 52 M | 48.3 M | 52 M | 48.3 M | 46.8 M | 46.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 353 M | 46.8 M | 189 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M |  USA |
 |
EDAP TMS S.A.
EDAP
|
86.1 M | - | - | $ 162 M |  France |
 |
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | USA |
 |
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
720 M | - | - | $ 3.31 B | USA |
 |
Eargo
EAR
|
132 M | - | - | $ 10.2 M | USA |
 |
LENSAR
LNSR
|
71.4 M | $ 5.6 | -2.78 % | $ 67 M | USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | USA |
 |
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | USA |
 |
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
188 M | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | USA |
 |
Outset Medical
OM
|
264 M | $ 4.04 | -4.49 % | $ 61.5 K | USA |
 |
AxoGen
AXGN
|
222 M | $ 39.49 | -0.6 % | $ 1.82 B | USA |
 |
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | USA |
 |
Insulet Corporation
PODD
|
3.19 B | $ 163.26 | 3.08 % | $ 11.5 B | USA |
 |
Quanterix Corporation
QTRX
|
419 M | $ 3.67 | -6.38 % | $ 156 M | USA |
 |
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | USA |
 |
Bruker Corporation
BRKR
|
6.24 B | $ 60.45 | -2.74 % | $ 9.18 B | USA |
 |
Sintx Technologies
SINT
|
9.51 M | $ 1.42 | -6.58 % | $ 3.94 M | USA |
 |
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | USA |
 |
TELA Bio
TELA
|
81.4 M | $ 0.69 | -2.81 % | $ 32.4 M | USA |
 |
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M |  Canada |
 |
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | USA |
 |
Tactile Systems Technology
TCMD
|
274 M | $ 27.48 | 0.15 % | $ 629 M | USA |
 |
TransMedics Group
TMDX
|
1.07 B | $ 72.26 | 1.59 % | $ 2.46 B | USA |
 |
IRIDEX Corporation
IRIX
|
29.2 M | $ 0.89 | -3.38 % | $ 15.1 M | USA |
 |
Tandem Diabetes Care
TNDM
|
881 M | $ 17.12 | 1.3 % | $ 1.16 B | USA |
 |
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | USA |
 |
Second Sight Medical Products
EYES
|
39.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
ClearPoint Neuro
CLPT
|
97.7 M | $ 14.12 | -2.55 % | $ 400 M | USA |
 |
Viemed Healthcare
VMD
|
199 M | $ 11.77 | 0.86 % | $ 458 M | USA |
 |
Avanos Medical
AVNS
|
1.07 B | $ 24.99 | 0.04 % | $ 1.16 B | USA |
 |
Beyond Air
XAIR
|
35.4 M | $ 5.16 | -5.67 % | $ 42.8 B | USA |
 |
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | USA |
 |
Xtant Medical Holdings
XTNT
|
94.1 M | $ 0.43 | -0.39 % | $ 60 M | USA |
 |
Cytosorbents Corporation
CTSO
|
44.2 M | $ 0.36 | -0.39 % | $ 22.4 M | USA |
 |
NanoVibronix
NAOV
|
41.1 M | - | - | $ 1.08 M | USA |
 |
NuVasive
NUVA
|
2.22 B | - | - | $ 2.07 B | USA |
 |
Natus Medical Incorporated
NTUS
|
564 M | - | 1.94 % | $ 1.05 B | USA |
 |
Nevro Corp.
NVRO
|
554 M | - | - | $ 217 M | USA |
 |
Inogen
INGN
|
299 M | $ 6.15 | -2.69 % | $ 164 M | USA |